RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

INTRODUCTION: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period, single-arm, exploratory study of RAM plus gefiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Nishio, Kazuto, Reck, Martin, Garon, Edward B., Imamura, Fumio, Kawaguchi, Tomoya, Yamaguchi, Hiroyuki, Ikeda, Satoshi, Hirano, Katsuya, Visseren-Grul, Carla, Ceccarelli, Matteo, Wijayawardana, Sameera R., Zimmermann, Annamaria, Matsui, Tomoko, Enatsu, Sotaro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966141/
https://www.ncbi.nlm.nih.gov/pubmed/35369607
http://dx.doi.org/10.1016/j.jtocrr.2022.100303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966141/
https://www.ncbi.nlm.nih.gov/pubmed/35369607
http://dx.doi.org/10.1016/j.jtocrr.2022.100303

Ejemplares similares